You are here: Industry Insights > trial

News List

Lilly's Trial Studying Higher Doses of Trulicity® (dulaglutide) Meets Primary Endpoint americanpharmaceuticalreview
June 27, 2019
Eli Lilly and Company's trial studying higher investigational doses of Trulicity® (dulaglutide) met its primary efficacy endpoint of superiority, significantly reducing A1C from baseline in people with type 2 diabetes, compared to once-weekly Trulicity 1.
TARIS Announces Positive Results of TAR-200 Trial americanpharmaceuticalreview
June 27, 2019
TARIS Bio™ announced positive safety, tolerability and preliminary efficacy data from the full patient cohort (n=20) of its Phase 1b study of TAR-200 for the treatment of patients with muscle invasive bladder cancer (MIBC), neoadjuvant to radical cystecto
Sound Pharmaceuticals Announces Positive Topline Results from SPI-1005 Phase 2b Trial americanpharmaceuticalreview
June 26, 2019
Sound Pharmaceuticals announced positive top-line results from a randomized, double-blind, placebo-controlled, multi-center Phase 2b study in Meniere's Disease (MD).
Dompé Announces First Patient Enrollment in Novel MOA Trial in Moderate to Severe Dry Eye Disease americanpharmaceuticalreview
June 26, 2019
Dompé Farmaceutici and Dompé announced the first patient has been enrolled in Study NGF0118, a multicenter, randomized, double-masked, vehicle-controlled, parallel group study to ...
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 americanpharmaceuticalreview
June 26, 2019
BioPharmX announced positive results from its Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.
Arena Announces First Subject Dosed in Etrasimod ELEVATE UC 52 Global Phase 3 Trial americanpharmaceuticalreview
June 20, 2019
Arena Pharmaceuticals announced the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials within the Phase 3 ELEVATE UC registrational program evaluating etrasimod 2 mg in subjects with moderately to severely active ulcerative col
Cellular Biomedicine Announces First Patient Dosing in Anti-CD20 Trial americanpharmaceuticalreview
June 20, 2019
Cellular Biomedicine Group has initiated its Phase I Clinical Trial of anti-CD20 Chimeric Antigen Receptor T-cell (CAR-T) targeting anti-CD19 treated, relapsed diffuse large B-cell lymphoma (DLBCL) and small B-cell lymphoma patients in China, and dosed th
Phase 2 Trial Shows Efficacy of CyTuVax’s Adjuvant Platform Technology b3cnewswire
June 20, 2019
Phase 2 Trial Shows Efficacy of CyTuVax’s Adjuvant Platform Technology.
Cellenkos Initiates CK0801 Trial for Bone Marrow Failure Syndromes americanpharmaceuticalreview
June 06, 2019
Cellenkos announced the initiation of a Phase 1 Clinical Trial of CK0801, a first-in-class, allogeneic cord blood-derived T-regulatory cell product, for treatment of patients with bone marrow failure syndromes...
Akero Therapeutics Initiates AKR-001 Phase 2a Clinical Trial for NASH americanpharmaceuticalreview
May 30, 2019
Akero Therapeutics announced it has screened the first patient for its Phase 2a clinical trial evaluating AKR-001, the company's lead product candidate for the treatment of NASH.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page